hydroxyproline as a urinary marker of bone resorption in osteoporotic patients (Eastell et al, 1990; Delmaset al, 1991; Paterson et al, 1991) .
Urinary excretion of cross-links has been reported to be elevated in patients with breast and prostate cancer (Sano et al, 1994) and to fall when bone metastases are treated by antiresorptive drugs such as bisphosphonates (Coleman et al, 1992) .
The aim of this study was to assess the ability of two urinary cross-link markers to predict response to hormonal treatment in patients with breast cancer bone metastases. These analytes were measured serially and compared with serum levels of the breast tumour-associated antigen CA15-3 (Robertson et al, 1991) and standard International Union Against Cancer (UICC) radiological criteria of response (Hayward et al, 1977) .
PATIENTS AND METHODS

Patients
Thirty-six women with breast cancer presenting with metastatic disease in the skeleton were prospectively studied. At relapse or progression of their disease, women were either being treated with adjuvant tamoxifen 20 mg day -1 (n = 13), megesterol acetate (n = 3), radiotherapy induced ovarian ablation (n = 1), or on no treatment (n = 19). Four patients presented synchronously with bone metastases and a palpable breast lump.
The diagnosis of bone metastases in all women was made by a radioisotope bone scan at presentation combined with plain Measurement of urinary collagen cross-links indicate response to therapy in patients with breast cancer and bone metastases radiographs of the chest, pelvis and lumbar spine. Radiographs were also taken of any areas of activity on the radioisotope scan or any clinically symptomatic areas of the skeleton. Twelve patients had disease in other sites (soft tissue, n = 8; lung, n = 7; liver, n = 2; brain, n = 1) (Table 1) . Sequential radiological monitoring was performed with plain radiographs of the chest, pelvis, lumbar spine and any other affected bones every 3 months. Response to treatment for patients with lytic metastases was assessed by standard radiological UICC criteria at 3 and 6 months, or at disease progression (Hayward et al, 1977) . The radiological response to treatment was assessed independently by a consultant radiologist and confirmed by a medical oncologist without knowledge of the cross-link results. Patients with an increase in the number of metastases, or size of metastases, or the development of further lytic metastases were regarded as having progressive disease.
Patients with solely sclerotic metastases were not evaluable according to UICC criteria and were excluded from the study. However, patients with mixed sclerotic and lytic disease, or patients with sclerotic metastases who had clearly evaluable areas of soft tissue disease were included.
For analysis, patients with responding or stable disease for more than 6 months were grouped together as these categories have been shown to demonstrate equivalent response (Robertson et al, 1997) . At relapse with bone metastases, all patients were fully staged radiologically and by liver function tests. Subsequently they were started on tamoxifen 20 mg day -1 (n = 21), megesterol acetate 160 mg day -1 (n = 5), Zoladex (n = 2), aminoglutethamide (n = 3), arimidex (n = 1) and chemotherapy (n = 1). Three women had been on adjuvant tamoxifen for over 5 years, and it was felt they might respond to tamoxifen withdrawal, thus they were given no treatment. No patient had received bisphosphonate therapy or skeletal radiotherapy prior to, or during, the study period. The study was approved by the Hospital Ethics Committee and all patients gave informed consent.
Methods
Blood samples were collected at each clinic visit, centrifuged, and stored at -20°C. Urine for measurement of Pyr, Dpyr, calcium, creatinine and cyclic adenosine monophosphate (cAMP) was collected between 10:00 h and 12:00 h, from patients who had fasted overnight. Urine was stored at -20°C after the addition of 3% hydrochloric acid. All samples were coded, and all samples from individual patients were assayed in the same batch. Following acid hydrolysis of urine at 110°C overnight, and partial purification on a CF1 cellulose column, Pyr and Dpyr were separated by reverse phase high-performance liquid chromatography (HPLC) and detected by fluorescence (Colwell et al, 1993) . The intra-assay coefficients of variation for Pyr and Dpyr were 7% and 10% respectively, and for inter-assay variation were <10%. Age-matched post-menopausal women had absolute ranges of Pyr of 12-40 nmol mmol -1 creatinine, and Pyr 3-11 nmol mmol -1 creatinine (Colwell et al, 1993) . The upper limits of normal for this study were therefore the highest levels measured in age-matched controls; Pyr 40 nmol mmol -1 creatinine and Dpyr 11 nmol mmol -1 creatinine. Urine excretion of cAMP was measured by radioimmunoassay (Amersham UK), and was expressed as nmol l -1 glomerular filtrate. The fasting molar ratio of urinary calcium to creatinine (CaCr -1 mmol mmol -1 ) was multiplied by the serum creatinine to calculate calcium excretion (CaE). CaE was then compared with serum calcium to assess the renal tubular reabsorption of calcium (Peacock et al, 1969) .
Serum calcium, creatinine, albumin, and alkaline phosphatase were measured by standard automated methods. Serum calcium was adjusted to an albumin concentration of 40 g l -1 (adjusted serum calcium = measured calcium mmol l -1 +0.02[40-measured albumin]). Blood for assay of plasma PTHrP was collected in EDTA after the addition of 200 IU of Trasylol, and separated by (Ratcliffe et al, 1993) . Serum CA15-3 was measured by an immunoradiometric assay (CIS UK Ltd; healthy controls >30 U ml -1 ). The percentage change of biochemical markers was calculated by using each patient as her own control. The subsequent increase or decrease in each tumour marker are expressed as a percentage change from the original value. This enables a comparison of magnitude of change between each tumour marker without any confusion as to the importance of absolute values. Variations of tumour markers within the reference range for healthy controls were recorded as no percentage change.
Statistical analysis was performed by Spearman rank correlation, Kruskal-Wallis three-way analysis, Mann-Whitney U-tests, and multiple analysis of variance where appropriate.
RESULTS
UICC assessment of disease response
The frequency of metastases in sites other than bone was equally distributed between patients with responding and progressing disease ( Table 1) . As evaluated by UICC criteria at 6 months, or at disease progression, 19 patients had radiological evidence of progressive disease, and 17 patients either had stable disease or a partial response. The median duration of response was 10 months (range 6-24 months). The median number of bone metastases initially detected in the women with progressive bone disease was five (range 1-12), and was not significantly different from the number found in women whose disease responded (median three, range 1-12). Eighteen women had lytic bone metastases, 14 had mixed sclerotic/lytic metastases, and four had sclerotic metastases with easily evaluable soft tissue metastases. Measurement of urinary cross-link excretion at the start of the study showed that Pyr correlated with Dpyr (r = 0.85, P < 0.0001).
The number of bone metastases was not related to the urinary levels of the two bone resorption markers and there was no significant relationship between them and the number of bone metastases at presentation. The frequency of metastases in sites other than bone was equally distributed between the progressive and non-progressive groups (Table 1) .
Biochemical parameters at the start of the study
A series of urine and biochemical measurements were made at the beginning of the study in order to see if any measurement predicted disease response ( Table 2 ). Excretion of Pyr was significantly higher in patients whose disease subsequently progressed (mean 164 nmol mmol -1 creatinine, range 35-291) compared with a mean of 56 nmol mmol -1 creatinine (range 20-75) in women who responded (partial response and stable disease) (P < 0.01) ( Figure 1A) .
Excretion of Dpyr was also higher in women with disease that progressed, mean 40 nmol mmol -1 creatinine (range 9-80) compared with a mean value in responders of 14 nmol mmol -1 creatinine (range 6-22) (P < 0.02) ( Figure 1B ). Tumour marker serum CA15-3 was also significantly higher in progressors (mean 210 IU, range 29-853) compared with responders (mean 99 IU, range 11-498) ( Figure 1C ) (P < 0.05). Serum CEA was also higher in progressors (mean 57, range 4-470) than in responders (mean 23, range 4-150) (P < 0.05).
Serum calcium, urine calcium/creatinine ratio, calcium excretion and plasma PTHrP were non-predictive (Table 2) . Although urine cAMP was significantly higher at the beginning of the study in progressors, sequential changes were not predictive ( Table 2) . The specificity and sensitivity of three predictive assays (Pyr, Dpyr and CA15-3) are shown in Table 3 .
Patients with responding bone metastases
Pyr and Dpyr excretion was within the normal range in 50% and 60% of cases respectively. Furthermore, the urinary concentrations of Pyr and Dpyr did not change significantly throughout the period of urine cross-link sampling, which was for a median of 6 months (range 3-12), and demonstrated for the first 2 months by Figure  2A and B.
Patients with progressive bone metastases
At initial diagnosis of skeletal metastases, urinary Pyr and Dpyr were increased in 100% and 85% of patients, respectively, who subsequently developed progressive disease ( Figure 1A,B) . The median follow-up time for a patient with progressive disease was 4 months (range 2-11). Over the period of monitoring, urinary Pyr and Dpyr excretion increased in all patients with progressive disease, compared with the levels at presentation. The initial rise in excretion preceded radiological evidence of disease progression by a median of 2 months (Figure 2A,B) . The increases in Pyr and Dpyr excretion were significant at 8 weeks (P < 0.04), and also at 12 weeks (P < 0.005) (Figure 2A,B) .
Calcium excretion and PTHrP levels
Urinary calcium excretion at presentation did not differ significantly between the patients who progressed or responded; mean 49 µmol LGF -1 (range 7-118) and 38 µmol LGF -1 (range 1-102) respectively. Neither calcium excretion nor the urinary calcium-creatinine ratio correlated with disease response. Renal tubular reabsorption of calcium was within the normal range for all patients. Plasma PTHrP levels were similar in both groups of patients: the median in the progressive group was <0.23 pmol l 
Comparison with changes in serum CA15-3 levels
In all patients, initial urinary Pyr and Dpyr levels correlated with serum CA15-3 (r = 0.86, P = 0.006; and r = 0.8, P = 0.01 respectively). In the group who progressed, median CA15-3 levels rose, and in the responders, median CA15-3 levels remained stable confirming the radiological UICC assessment of disease progression. However, CA15-3 levels increase from the first measurement in some responders, and decreased in some progressors ( Figure  3A,B) .
DISCUSSION
The recent development of sensitive biochemical markers to determine changes in bone metabolism has provided new insights into the mechanisms of progression of bone metastases in women with breast cancer. Pyr and Dpyr have both been shown to be more sensitive than urinary hydroxyproline in monitoring bone resorption (Eastell et al, 1990; Bettica et al, 1992; Colwell et al, 1993) .
We have confirmed the preliminary findings of a recent study which reported increased Pyr and Dpyr in patients with bone metastases from breast cancer (Paterson et al, 1991) . Dpyr has previously been shown to decrease transiently in 20 patients with bone metastases undergoing chemotherapy, suggesting that Dpyr may be a useful early marker of disease response to therapy (Wada et al, 1993) . We have demonstrated that the initial urine levels of Pyr and Dpyr in patients presenting with bone metastases allows prediction of future outcome of the disease. The positive predictive values that indicated the disease progression for Pyr and Dpyr were 95% and 100% for urine levels of 70 and 22 nmol mmol -1 creatinine respectively. This compares very favourably with the standard tumour marker Ca15-3, where even with levels twice the upper limit of normal, sensitivity and specificity for disease progression was only 82% and 79%. Both Pyr and Dpyr increased significantly within 8 weeks in progressors. The measurement of urinary cross-links provided objective disease response assessment by 2 months compared to the standard criteria, which require 3-6 months of radiological assessment (Hayward et al, 1977; Coleman et al, 1998) . Biochemical markers would thus allow earlier changes of therapy for women with progressive disease and may result in better patient outcomes.
CA 15-3 is released from human tumour cells, and is the most reliable biochemical tumour marker currently available for monitoring response to treatment in patients with advanced breast cancer. Although increased levels of CA 15-3 are useful, rises in CA 15-3 can occur in the first 3 months in some patients who subsequently respond to therapy, and should be regarded with caution. In contrast, Pyr and Dpyr are released from the bone matrix by osteoclast-mediated resorption stimulated by the tumour-produced factors. CA 15-3 is not produced by every tumour and does not always reliably increase even when the tumour is progressing (Robertson et al, 1991) . However, CA 15-3 is of great value for monitoring metastases at other sites. Women who present with elevated urinary levels of cross-links appear to respond poorly to changes in hormonal therapy.
Breast cancer may affect bone metabolism, producing increased bone resorption with or without an associated increase in bone formation (Delmas et al, 1991; Sano et al, 1994) . Bone resorption is increased by factors released by breast cancer cells such as PTHrP, TGF-α, or prostaglandins, which may stimulate osteoclastic activity either locally or via the bloodstream (Mundy et al, 1985) . Bone metastases usually stimulate bone resorption more than bone formation and thus markers of bone formation, e.g. alkaline phosphatase, are not as valuable markers of disease activity as markers of bone degradation such as Pyr and Dpyr.
Urinary cAMP excretion was raised at presentation in those patients who subsequently had progressive disease. It did not, however, rise sequentially with disease progression, and could not be utilized as a marker of disease response. Urinary cAMP was elevated in the absence of raised PTHrP, and this may reflect the actions of an as yet unidentified tumour product that affects the kidney. In contrast to previous authors (Coleman et al, 1988; Dodwell et al, 1990) we were unable to demonstrate a significant increase in urinary calcium excretion in patients with progressive bone disease. Urinary calcium excretion does not change in the presence of sclerotic bone metastases, whereas urinary cross-link excretion was shown to be elevated (Sano et al, 1994) . In this study, 50% of the women had an element of sclerotic bone disease, and this may account for the failure of urinary calcium excretion to increase with disease progression. As with other markers of bone disease, elevation of urinary cross-link levels must be related to other clinical and biochemical markers as elevations of urinary cross-links could occur from benign bone disease. These results confirm work by Sano et al (1994) that bone resorption is also elevated in patients with osteosclerotic bone metastases despite the osteoblastic overactivity seen on histological and radiological study of such metastases. This study has demonstrated that sequential monitoring of urinary cross-link levels during therapy may prove to be a useful indicator of disease response in bone.
